Senior Vice President of Celgene Global Health and Global Medical Affairs, Celgene
Dr. Joseph S. Camardo, MD, is a Member of the American College of Physicians Foundation and currently serves as Senior Vice President-Global Medical Affairs and Global Health at Celgene Corp. Dr. Camardo is also on the Board of Directors at ScripsAmerica, Inc., Mali Health Organizing Project and Rosemont College. Prior to Celgene, Dr. Camardo served at several leading pharmaceuticals companies, including Forest Laboratories, Pfizer and Wyeth, where he held senior positions in Medical Affairs. He received his B.A. with a major in Biology from the University of Pennsylvania, and a doctorate in Internal Medicine from The Perelman School of Medicine, University of Pennsylvania
Co- Founder and President, Baruch S. Blumberg Institute and the Hepatitis B Foundation
Dr. Tim Block is Co- Founder and President of the Baruch S. Blumberg Institute and the Hepatitis B Foundation, which established the Institute in 2003 to advance its research mission to find a cure for hepatitis B. He has been involved in hepatitis research for more than 25 years and is internationally recognized for his scholarship and scientific contributions to the field. Dr. Block was a tenured Professor at Thomas Jefferson University for 20 years and at Drexel University College of Medicine for 10 years.
Director, Liver cancer research, Massachusetts General Hospital Cancer Center
Dr. Andrew X. Zhu is Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma through phase I, II and III clinical trials. The second area of his research interests is directed at the development of novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area of his research is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma and assess their potential correlation with clinical outcomes and as therapeutic targets
As a widely published author, Dr. Zhu has served as a principle investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. He is the invited reviewer for many medical journals and has lectured extensively on HCC and other gastrointestinal cancers. An internationally recognized leader in HCC and cholangiocarcinoma, he has led early efforts of developing several molecularly targeted agents in liver cancers and studying the predictive and surrogate circulating and imaging biomarkers. He is a founding board member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research. Dr. Zhu serves on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, and the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee (GISC). He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award
Head, Quantitative Sciences, Bill & Melinda Gates Medical Research Institute
Dr. Jeffrey S. Barrett, Ph.D. is Head of Quantitative Sciences at Bill & Melinda Gates Medical Research Institute. He also serves as Vice-President at Sanofi, as Global Head of Translational Informatics, Pediatric Clinical Pharmacology, and Interdisciplinary Pharmacometrics Program (IPP). He was professor of Pediatrics at The Children's Hospital of Philadelphia & the University of Pennsylvania. He is now Adjunct Professor at famous universities including the University of Pennsylvania, the University of Tennessee and the University of Florida. Prior to Bill & Melinda Gates Medical Research Institute, Dr. Jeffrey S. Barrett worked at several leading pharmaceuticals companies or laboratories including Sanofi Pharmaceuticals, Aventis Pharmaceuticals, DuPont Pharmaceuticals Company, Somerset Pharmaceuticals and Merck Research Laboratories. He received his Ph.D. and M.S. majoring in Pharmacokinetics from the University of Michigan.
Former Executive Director of Clinical Research at Celgene, Chief Editor of 《Leukemia》，Visiting Professor of Imperial College London.
Dr. Gale is a physician and medical researcher，he received a Ph.D. in microbiology and immunology from the University of California, Los Angeles. His areas of research include Leukemia and other bone marrow disorders. He is an expert in leukemia biology, etiology/causation and therapy, bone marrow transplantation, lymphoma and multiple myeloma. Dr. Gale was on the faculty of UCLA, is currently on the Medical Staff and is Visiting Professor of Haematology at the Imperial College London. He has published over 800 scientific articles and more than 20 books, mostly on Leukemia, transplantation，cancer immunology and radiation ,he was Executive Director of Clinical Research ,hematology and oncology at Celgene.